Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Multicenter Study of Immediate Postoperative Instillation of Gemcitabine in Patients With Superficial Transitional Cell Carcinoma of the Bladder

NCT00191477 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00191477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00191477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Multicenter Study of Immediate Postoperative Instillation of Gemcitabine in Patients With Superficial Transitional Cell Carcinoma of the Bladder
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Terminated
Start date
January 31, 2004
Completion date
June 30, 2008
Enrollment
355 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder neoplasms